Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study

Novo Nordisk (NVO) shares climbed about 9% on Mar 7 and continued to gain another 1.4% in the after-market hours, following the company’s presentation of efficacy data from a phase I study on its new oral obesity pill, amycretin, at its Capital Markets Day.In the completed phase I study of oral amycretin, it was observed that the treatment of patients with amycretin resulted in a reduction of 13.1% in body weight compared with a decrease of 1.1% in the placebo arm after 12 weeks. Amycretin has shown faster ...